TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25684089

Group type: EXPERIMENTAL
Intervention: Plant-based diet (PB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: American Heart Association diet (AHA)
Number of subjects: 30
Study: 23106760

Group type: EXPERIMENTAL
Intervention: Group drug counseling with positive alliance with counselor
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Group drug counseling with advice from counselor and group members
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Group drug counseling with self-disclosure and participation
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Changes in process variables over time (linear slopes)
Number of subjects: 440
Study: 20579938

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.2-0.4 mg daily)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Alarm
Number of subjects: 251
Study: 18922243

Group type: EXPERIMENTAL
Intervention: Escitalopram 5-10 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/d
Number of subjects: 0
Study: 17012890

Group type: EXPERIMENTAL
Intervention: DTPw-HepB-Hib combination vaccine (Quinvaxem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPw-Hib and hepatitis B vaccines (comparator group)
Number of subjects: 0
Study: 14609821

Group type: EXPERIMENTAL
Intervention: Umbilical cord serum therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Autologous serum therapy
Number of subjects: 59
Study: 10921767

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg via Turbuhaler
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg via Turbuhaler
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg via pMDI
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg via pMDI
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9220839

Group type: EXPERIMENTAL
Intervention: Unna's boot and activated charcoal treatment
Number of subjects: 47
Study: 1374061

Group type: EXPERIMENTAL
Intervention: Local + HBI (800 cGy)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Local only (300 cGy x 10)
Number of subjects: 499
Study: 4018464

Group type: EXPERIMENTAL
Intervention: Mental stress (mental arithmetic and Sacks test)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ambulatory ECG monitoring
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Mental arithmetic
Number of subjects: 130
Study: 30908136

Group type: EXPERIMENTAL
Intervention: Mindfulness coloring (mandala)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Free drawing/coloring
Number of subjects: 167

Group type: COMPARATOR
Intervention: Noncoloring control activity
Number of subjects: 167
Study: 26558649

Group type: EXPERIMENTAL
Intervention: Standardized consent form with additional printed take-home material
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standardized consent form without additional printed take-home material
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Standardized consent form with written information
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standardized consent form without written information
Number of subjects: 100
Study: 26667403

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (10 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 64
Study: 24218006

Group type: EXPERIMENTAL
Intervention: Basel cocktail (low doses of caffeine, efavirenz, losartan, omeprazole, metoprolol, midazolam)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Basel cocktail
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DBS or saliva samples
Number of subjects: 16
Study: 22198456

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 84

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 84
Study: 20660832

Group type: EXPERIMENTAL
Intervention: R-ICE
Number of subjects: 396

Group type: COMPARATOR
Intervention: R-DHAP
Number of subjects: 396
Study: 18310583

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CCBT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CCBT) followed by mirtazapine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 15650277

Group type: EXPERIMENTAL
Intervention: PregVit p.m. (1 tablet containing 1.1 mg of folic acid) administered in the morning
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PregVit p.m. (1 tablet containing 1.1 mg of folic acid) administered in the evening
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PregVit p.m. (morning administration)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PregVit p.m. (evening administration)
Number of subjects: 6
Study: 11828241

Group type: EXPERIMENTAL
Intervention: ULLS-CM (countermeasures)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ULLS-CON (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AMB-CM (countermeasures)
Number of subjects: 32

Group type: COMPARATOR
Intervention: AMB-CON (control)
Number of subjects: 32
Study: 10405497

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg per dose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg per dose
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 11
Study: 7564509

Group type: EXPERIMENTAL
Intervention: L-asparaginase
Number of subjects: 154

Group type: COMPARATOR
Intervention: Etoposide
Number of subjects: 154
Study: 2374231

Group type: EXPERIMENTAL
Intervention: Caudal epidural anesthesia with 0.33 ml.kg.‐1 0.25% bupivacaine before surgery (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Caudal epidural anesthesia with 0.33 ml.kg.‐1 0.25% bupivacaine after surgery (group B)
Number of subjects: 24
Study: 6773715

Group type: EXPERIMENTAL
Intervention: tocainide 600 mg three times daily for 8 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: quinidine sulfate 300 mg four times daily for 8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo administered for 6 weeks
Number of subjects: 41
Study: 30365198

Group type: EXPERIMENTAL
Intervention: Denture wipe
Number of subjects: 152

Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 152
Study: 28641496

Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27146258

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50 μg (2000 IU) daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50 μg per day
Number of subjects: 42
Study: 24661355

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 75 μg (3000 IU) daily for 6 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22539589

Group type: EXPERIMENTAL
Intervention: Trained (TR, n = 18, 4-month exercise program)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nontrained (NT, n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Liposuction
Number of subjects: 36
Study: 20350694

Group type: EXPERIMENTAL
Intervention: Automated health monitoring (AHM) system in conjunction with SPAN-CHF disease management program
Number of subjects: 188

Group type: COMPARATOR
Intervention: Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) disease management program
Number of subjects: 188
Study: 18936596

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg followed by an additional dose of parecoxib 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15619066

Group type: EXPERIMENTAL
Intervention: Endovascular interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vascular surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery of a ruptured aneurysm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid, aneurysm, and bypass surgery
Number of subjects: 0
Study: 14716525

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 176

Group type: COMPARATOR
Intervention: Unrestricted diet
Number of subjects: 176
Study: 10516516

Group type: EXPERIMENTAL
Intervention: Isokinetic exercise with the Cybex 6000 dynamometer
Number of subjects: 67

Group type: COMPARATOR
Intervention: Isometric exercise with the Cybex 6000 dynamometer
Number of subjects: 67
Study: 8684198

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.1 to 0.5 microgram/kg per min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 to 10 micrograms/kg per min
Number of subjects: 23
Study: 1653363

Group type: EXPERIMENTAL
Intervention: Granisetron (BRL 43694A) - single intravenous dose
Number of subjects: 152

Group type: COMPARATOR
Intervention: Dexamethasone plus prochlorperazine
Number of subjects: 152
Study: 6401422

Group type: EXPERIMENTAL
Intervention: Balanced substrate formula (40 kcal/kg/day, 1 to 1.5 g protein/kg/day, carbohydrate-nitrogen ratio 50:1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 25% dextrose and 4.25% protein solution (50 kcal/kg/day, 1 to 1.5 g protein/kg/day, carbohydrate-nitrogen ratio 150:1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (nonseptic patients receiving balanced substrate formula)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (nonseptic patients receiving 25% dextrose and 4.25% protein solution)
Number of subjects: 22
Study: 31659854

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wakeful state
Number of subjects: 32
Study: 28688174

Group type: EXPERIMENTAL
Intervention: 200 mL of tomato juice (TJ)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 400 mL of tomato juice (TJ)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 28
Study: 25820048

Group type: EXPERIMENTAL
Intervention: Educational intervention (6 educational sessions)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (non-interventional schools)
Number of subjects: 1000
Study: 23886261

Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib (T + S group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: TACE alone (T group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sorafenib alone (S group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib (T + S group) and Sorafenib alone (S group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib (T + S group) and TACE alone (T group)
Number of subjects: 79
Study: 21236730

Group type: EXPERIMENTAL
Intervention: Parotid-sparing IMRT
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 94
Study: 19520595

Group type: EXPERIMENTAL
Intervention: RAPID‐3
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: RADAI‐5
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: DAS28‐ESR
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CDAI
Number of subjects: 128
Study: 17544491

Group type: EXPERIMENTAL
Intervention: d-amphetamine 15 mg/70 kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: d-amphetamine 0 mg (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-amphetamine 3.125 mg/70 kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-amphetamine 7.5 mg/70 kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sublingual estradiol 0.25 mg
Number of subjects: 10
Study: 15460844

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11008994

Group type: EXPERIMENTAL
Intervention: CPR-video protocol
Number of subjects: 335

Group type: COMPARATOR
Intervention: CPR-social support intervention
Number of subjects: 335

Group type: COMPARATOR
Intervention: CPR-instructor protocols
Number of subjects: 335
Study: 8774514

Group type: COMPARATOR
Intervention: Exosurf
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Infasurf
Number of subjects: 1126
Study: 1502481

Group type: EXPERIMENTAL
Intervention: Baker's yeast capsules
Number of subjects: 19

Group type: COMPARATOR
Intervention: Yeast exclusion (no dietary yeast)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Baseline (usual diet)
Number of subjects: 19
Study: 6380447

Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (2 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31372970

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) using routine outcome monitoring (ROM) in a national trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) during the intake in a regional trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine outcome monitoring (ROM) in clinical practice
Number of subjects: 0
Study: 29515256

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/folinic acid (5FU/FA)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: gemcitabine
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/folinic acid (5FU/FA) with low hENT1 expression
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: gemcitabine with low hENT1 expression
Number of subjects: 238
Study: 1358496

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microgram/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microgram/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 microgram/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 22694757

Group type: EXPERIMENTAL
Intervention: Fasudil
Number of subjects: 0
Study: 20555311

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg/day for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18691985

Group type: EXPERIMENTAL
Intervention: epinastine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ketotifen
Number of subjects: 40

Group type: COMPARATOR
Intervention: azelastine
Number of subjects: 40
Study: 15914352

Group type: EXPERIMENTAL
Intervention: Meconium-stained amniotic fluid (MSAF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No meconium-stained amniotic fluid (non-MSAF)
Number of subjects: 30
Study: 12887344

Group type: EXPERIMENTAL
Intervention: PRP/BPBM/GTR (experimental group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open flap debridement (control group)
Number of subjects: 52
Study: 10381285

Group type: EXPERIMENTAL
Intervention: Alpha-carotene
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 74

Group type: COMPARATOR
Intervention: Alpha-tocopherol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ubiquinol-10
Number of subjects: 74
Study: 8873009

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Number of subjects: 19
Study: 1793242

Group type: EXPERIMENTAL
Intervention: gentamicin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: neomycin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: silver sulfadiazine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: mupirocin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Omiderm (control)
Number of subjects: 5
Study: 6732217

Group type: EXPERIMENTAL
Intervention: 250 mg of Sch 29,482 orally every 6 h for 4 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo orally every 6 h for 4 days
Number of subjects: 58
Study: 30669897

Group type: EXPERIMENTAL
Intervention: Early palmar plating (surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Initial nonoperative treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Delayed surgery (for secondary displacement)
Number of subjects: 80
Study: 28768446

Group type: EXPERIMENTAL
Intervention: Temsirolimus 175/75 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Temsirolimus 75 mg
Number of subjects: 89
Study: 26632632

Group type: EXPERIMENTAL
Intervention: Local infiltration anaesthetic (LIA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24633171

Group type: EXPERIMENTAL
Intervention: Gentle, non-pain-based language
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard language
Number of subjects: 0
Study: 21940133

Group type: EXPERIMENTAL
Intervention: HeartSaver Sticker (n=26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No HeartSaver Sticker (n=25)
Number of subjects: 51
Study: 19825908

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release 12 mg on days 1-6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone immediate-release 2 mg on day 1 and 4 mg on days 2-6
Number of subjects: 0
Study: 18043445

Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine (WC3) reassortant rotavirus vaccine
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2070
Study: 19957383

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced musculoskeletal ultrasonography (CE-MUS) with SonoVue
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Power Doppler sonography (PDS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Contrast-enhanced magnetic resonance imaging (CE-MRI) with Magnevist
Number of subjects: 41

Group type: COMPARATOR
Intervention: B-mode ultrasound (US)
Number of subjects: 41

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 41
Study: 15466681

Group type: EXPERIMENTAL
Intervention: ImPACT intervention (1-session, videotape and discussion)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: ImPACT intervention (with boosters)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Focus on Kids (FOK)
Number of subjects: 817
Study: 11762657

Group type: EXPERIMENTAL
Intervention: IUCD insertion immediately after abortion
Number of subjects: 0
Study: 9263381

Group type: EXPERIMENTAL
Intervention: Nicorette chewing gum (ad libitum)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 21
Study: 8450527

Group type: EXPERIMENTAL
Intervention: active-atenolol
Number of subjects: 46

Group type: COMPARATOR
Intervention: placebo-atenolol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: nifedipine treated patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: captopril treated patients
Number of subjects: 46
Study: 3544744

Group type: EXPERIMENTAL
Intervention: Etretinate (10 mg capsule once a day)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 157
Study: 11573626

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 30922302

Group type: EXPERIMENTAL
Intervention: ICS continued group
Number of subjects: 1144

Group type: COMPARATOR
Intervention: ICS withdrawal group
Number of subjects: 1144
Study: 29465649

Group type: EXPERIMENTAL
Intervention: Metronidazole 750 mg + miconazole 200 mg intravaginal suppositories for 5 consecutive nights each month for 12 months
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo for 5 consecutive nights each month for 12 months
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 234
Study: 27595688

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Standard therapy without ICD
Number of subjects: 1116
Study: 24198342

Group type: EXPERIMENTAL
Intervention: EMG-triggered electrical stimulation to the four muscle groups of the affected arm plus usual therapy five times a week for four weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual therapy only
Number of subjects: 33
Study: 21933805

Group type: EXPERIMENTAL
Intervention: Leaflet giving information about ovarian/cervical cancer
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Cancer experts
Number of subjects: 146
Study: 19900131

Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (SH)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Total hysterectomy (TH)
Number of subjects: 132
Study: 17905507

Group type: EXPERIMENTAL
Intervention: ExP-A with blot-drying
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ExP-E with short evaporation (2-3s)
Number of subjects: 32
Study: 16154196

Group type: EXPERIMENTAL
Intervention: Intravitreous pegaptanib (0.3 mg)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 172
Study: 12190957

Group type: EXPERIMENTAL
Intervention: TUDCA (1000 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: UDCA (750 mg)
Number of subjects: 8
Study: 9930158

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) once a day starting 2 days before surgery until the fifth postoperative week and diclofenac eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) once a day starting 2 days before surgery until the fifth postoperative week and fluorometholone eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latanoprost placebo once a day starting 2 days before surgery until the fifth postoperative week and diclofenac eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latanoprost placebo once a day starting 2 days before surgery until the fifth postoperative week and fluorometholone eyedrops 4 times a day before surgery on the day of surgery and 3 times a day until the fifth postoperative week (Group D)
Number of subjects: 0